Harnessing CAR T-cell Insights to Develop Treatments for Hyperinflammatory Responses in Patients with COVID-19

Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with COVID-19 by repurposing existing drugs previously developed for cancer therapy.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer discovery 2020-06, Vol.10 (6), p.775-778
Hauptverfasser:	Agarwal, Sangya, June, Carl H
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Betacoronavirus Calcineurin Inhibitors - therapeutic use Cell- and Tissue-Based Therapy Coronavirus Infections - complications Coronavirus Infections - epidemiology COVID-19 Cytokines - metabolism Drug Repositioning Humans Immunotherapy - methods In Focus Inflammation - epidemiology Inflammation - etiology Inflammation - therapy Lymphohistiocytosis, Hemophagocytic - etiology Lymphohistiocytosis, Hemophagocytic - prevention & control Lymphohistiocytosis, Hemophagocytic - therapy Macrophage Activation Morbidity Neoplasms - therapy Neoplasms - virology Pandemics Pneumonia, Viral - complications Pneumonia, Viral - epidemiology Receptors, Antigen, T-Cell - immunology SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Cytokine release and macrophage activation contribute to immunopathology after SARS-CoV-2 infection. We discuss approaches to decrease the morbidity and mortality in patients with COVID-19 by repurposing existing drugs previously developed for cancer therapy.
ISSN:	2159-8274 2159-8290
DOI:	10.1158/2159-8290.CD-20-0473